RET and non-small cell lung carcinoma: In conclusion, we present a case of a patient with advanced CD74-ROS1 fusion NSCLC who acquired resistance to lorlatinib concurrent with developing a novel RUFY1-RET fusion, with both oncogenic fusion events identified on RNA NGS only.